Blood Cancer: New ‘Trojan Horse’ Drug for England Patients
England is at the forefront of blood cancer treatment with the introduction of a revolutionary “Trojan horse” drug, belantamab mafodotin. This innovative therapy is designed to target and destroy cancer cells from within, offering new hope to the estimated 1,500 patients annually battling multiple myeloma, a type of blood cancer. Patients can possibly experience remission three times longer than with customary treatments. The National institute for Health and Care Excellence (NICE) approved the drug, which is administered via infusion and has shown promising results in clinical trials. As the first healthcare system to implement this, the NHS is poised to transform the lives of those impacted. Discover how News Directory 3 will keep you posted on these life-changing breakthroughs and the future of cancer care.
England First to Offer “Trojan Horse” Drug for Blood Cancer Treatment
Thousands of patients in England battling blood cancer are set to receive a groundbreaking “Trojan horse” drug. This innovative treatment, belantamab mafodotin, is designed to infiltrate cancer cells and destroy them from within.
The National Institute for Health and Care Excellence (Nice) has approved the drug, offering new hope to those with multiple myeloma. Belantamab mafodotin can delay the progression of this cancer three times longer than standard treatments.
administered as an infusion every three weeks alongside other cancer drugs, this targeted therapy is a special antibody that seeks out and binds to cancer cells. The “Trojan horse” moniker comes from its mechanism: the drug enters the cancer cell and releases a concentrated dose of a lethal molecule, effectively eliminating the cell from the inside.
NHS England‘s national clinical director for cancer, Peter Johnson, said the new blood cancer treatment would be life-changing. “Myeloma is an aggressive type of blood cancer, but we have seen a steady advancement in the outlook for patients over recent years as we have introduced new targeted therapies,” Johnson said. “I am delighted that patients in England will be the first to benefit from this new treatment.”
Approximately 1,500 patients in England with multiple myeloma, an incurable bone marrow cancer, are expected to benefit each year. The drug, also known as Blenrep and manufactured by GlaxoSmithKline, will be available to patients whose cancer has advanced or has not responded to initial treatments.
Shelagh McKinlay, director of research and advocacy at Myeloma UK, hailed the NHS for being the first healthcare system to implement the new myeloma treatment. “We have been working very hard for the last year to get this treatment approved and we certainly know it will transform the lives of thousands of people with myeloma,” mckinlay said.
Paul Silvester, 60, of Sheffield, experienced remarkable results after being diagnosed with myeloma in 2023. After his initial treatment failed, he received belantamab mafodotin through an early access program at the royal Hallamshire Hospital.”I feel like this treatment has brought the party balloons back in the house,” Silvester said. “It has been amazing – within the first two or three weeks, after the first dose, I was in remission.”
Clinical trials indicate that belantamab mafodotin, when combined with bortezomib and dexamethasone, can delay disease progression by an average of three years. This is a significant improvement compared to the one-year delay seen with daratumumab and other treatments.
Helen Knight, director of medicines evaluation at Nice, emphasized the institution’s commitment to providing timely access to optimal care while ensuring value for taxpayers. Health Minister Karin Smyth added, “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”
What’s next
With the rollout of belantamab mafodotin, also known as Blenrep, England is poised to lead the way in innovative cancer care, offering a potential lifeline to thousands battling multiple myeloma. Further research and long-term monitoring will be crucial to fully understand the drug’s impact and optimize its use in treating this challenging disease.